Recent debate about potential long-term safety of gadolinium-based contrast agents has amplified concerns about their use in pregnancy, greatly limiting options for advanced imaging in this critical patient group. We report our experience on the use of ferumoxytol contrast-enhanced magnetic resonance angiography (MRA) during pregnancy. We identified eight pregnant subjects, at two institutions, with contrast-enhanced MRI/MRA using ferumoxytol. There was one mild possible adverse event during contrast administration. There were no premature deliveries (< 35 weeks) or birth defects in five babies with available postpartum data. While preliminary, ferumoxytol holds promise as a versatile MR contrast agent in pregnancy.